Table 3.
Joint effect of all biomarkers on RECIST-based progression and mortality rates in Pembro and Nivo cohorts estimated through the multivariable Cox regression analysis.
| Cohort | Biomarker and Levels | PFS (RECIST) | OS | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CL | p-Value | HR | 95% CL | p-Value | ||
| PC | sPD-L1 | 0.030 * | 0.215 | ||||
| 0.0–24.2 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 24.3–70.1 | 2.16 | 1.08–4.33 | 1.77 | 0.72–4.37 | |||
| sB7-H3 | 0.001 * | 0.011 * | |||||
| 0.0–0.5 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 0.6–472.9 | 0.32 | 0.17–0.64 | 0.33 | 0.14–0.78 | |||
| sB7-H4 | 0.001 * | 0.036 * | |||||
| 0.0–63.9 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 64.0–265.4 | 0.32 | 0.16–0.64 | 0.42 | 0.19–0.94 | |||
| IFNG | 0.362 | 0.021 * | |||||
| 0.2–1.0 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 1.1–4.1 | 0.73 | 0.38–1.43 | 2.95 | 1.18–7.36 | |||
| NC | sPD-L1 | 0.247 | 0.399 | ||||
| 0.0–24.7 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 24.8–94.2 | 0.79 | 0.53–1.18 | 0.84 | 0.56–1.26 | |||
| sB7-H3 | 0.068 | 0.009 * | |||||
| 0.0–0.4 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 0.5–33.6 | 0.69 | 0.46–1.03 | 0.54 | 0.34–0.86 | |||
| sB7-H4 | 0.743 | 0.932 | |||||
| 0.0–51.4 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 51.5–738.1 | 1.07 | 0.71–1.60 | 1.02 | 0.67–1.56 | |||
| IFNG | 0.861 | 0.203 | |||||
| 0.4–1.0 | 1.00 | (Ref.) | 1.00 | (Ref.) | |||
| 1.1–16.1 | 1.04 | 0.69–1.55 | 1.32 | 0.86–2.03 | |||
Legend—HR: hazard rate ratio adjusted for gender, age, cycles of therapy, ECOG-PS and histotype; 95% CL: 95% confidence limits for HR; p-value: probability level associated with the likelihood ratio test result; ref.: reference category (lower levels of biomarkers). * p < 0.05.